Sunil S.SDhawanMD

Dermatology • Fremont, CA

Center for Dermatology Cosmetic and Laser Surgery

Join to view full profile

Dr. Dhawan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dhawan's full profile

Already have an account?

Office
2557 Mowry Ave
Ste 34
Fremont, CA 94538
Phone+1 510-797-4111

Fax+1 510-797-3320

Education & Training

Mount Sinai Medical Center of Florida, IncResidency, Dermatology, 1987 - 1990
University of California (San Francisco)/Mount ZionResidency, Internal Medicine, 1983 - 1986
Keck School of Medicine of the University of Southern CaliforniaClass of 1983

Certifications & Licensure

CA State Medical License 1984 - 2026
FL State Medical License 1987 - 1998
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Top MD Consumers Checkbook
Fellow (FAAD) American Academy of Dermatology

Clinical Trials

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Start of enrollment: 2013 Nov 01
Completed
Phase 3
VPD-737 for Treatment of Chronic Pruritus Start of enrollment: 2013 Oct 15
Completed
Phase 2
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis Start of enrollment: 2014 Apr 01
Completed
Phase 2
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities Start of enrollment: 2014 May 01
Completed
Phase 3
Twelve Month Follow-Up of CP0108 Start of enrollment: 2014 Aug 01
Completed
Finasteride Treatment of Severe Nodulocystic Acne Start of enrollment: 2015 Jul 01
Completed
Phase 2
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis Start of enrollment: 2020 Jun 04
Completed
Phase 2
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment Start of enrollment: 2023 Nov 06
Recruiting
Phase 3
Roles: Principal Investigator
Using a Novel Skin Tag Removal Device Start of enrollment: 2024 Jun 03
Recruiting
Not Applicable
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

51 citations
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind C...
Angela Yen Moore, Lawrence Green, Suzanne Bruce, Neil S. Sadick, Eduardo Tschen
Journal of Drugs in Dermatology. 2018-09-01
31 citations
A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies
Linda Stein Gold, Sunil Dhawan, Jonathan S. Weiss, Zoe Diana Draelos, Herman Ellman
Journal of the American Academy of Dermatology. 2019-01-01
6 citations
Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX101 4% Minocycline Foam for Moderate-to-Severe Acne Vulgaris.
Linda Stein Gold, Sunil Dhawan, Jonathan S. Weiss, Zoe Diana Draelos, Herman Ellman
The Journal of Clinical and Aesthetic Dermatology. 2019-10-01

Professional Memberships

American Academy of Dermatology - AAD
Fellow